Sino Medical Sciences Technology Balance Sheet Health
Financial Health criteria checks 5/6
Sino Medical Sciences Technology has a total shareholder equity of CN¥898.8M and total debt of CN¥206.2M, which brings its debt-to-equity ratio to 22.9%. Its total assets and total liabilities are CN¥1.3B and CN¥381.2M respectively.
Key information
22.9%
Debt to equity ratio
CN¥206.24m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥224.94m |
| Equity | CN¥898.85m |
| Total liabilities | CN¥381.22m |
| Total assets | CN¥1.28b |
Recent financial health updates
Is Sino Medical Sciences Technology (SHSE:688108) Using Debt Sensibly?
Nov 19
Is Sino Medical Sciences Technology (SHSE:688108) Using Debt In A Risky Way?
Feb 28Recent updates
Is Sino Medical Sciences Technology (SHSE:688108) Using Debt Sensibly?
Nov 19Revenues Tell The Story For Sino Medical Sciences Technology Inc. (SHSE:688108) As Its Stock Soars 25%
Sep 24What Sino Medical Sciences Technology Inc.'s (SHSE:688108) P/S Is Not Telling You
Jun 03Optimistic Investors Push Sino Medical Sciences Technology Inc. (SHSE:688108) Shares Up 26% But Growth Is Lacking
Mar 05Is Sino Medical Sciences Technology (SHSE:688108) Using Debt In A Risky Way?
Feb 28Financial Position Analysis
Short Term Liabilities: 688108's short term assets (CN¥372.6M) exceed its short term liabilities (CN¥156.7M).
Long Term Liabilities: 688108's short term assets (CN¥372.6M) exceed its long term liabilities (CN¥224.5M).
Debt to Equity History and Analysis
Debt Level: 688108 has more cash than its total debt.
Reducing Debt: 688108's debt to equity ratio has increased from 0% to 22.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 688108 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 688108 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 8.4% per year.